Berenberg Bank Raises Abcam (LON:ABC) Price Target to GBX 1,400

Abcam (LON:ABC) had its price objective lifted by research analysts at Berenberg Bank from GBX 1,350 ($17.64) to GBX 1,400 ($18.29) in a research report issued to clients and investors on Tuesday, Digital Look reports. The brokerage presently has a “hold” rating on the stock. Berenberg Bank’s target price would indicate a potential downside of 5.98% from the stock’s previous close.

Separately, Liberum Capital raised their target price on Abcam from GBX 1,400 ($18.29) to GBX 1,450 ($18.94) and gave the company a “hold” rating in a research report on Wednesday, August 4th. Five equities research analysts have rated the stock with a hold rating, Based on data from, the stock has an average rating of “Hold” and a consensus target price of GBX 1,442 ($18.84).

Shares of Abcam stock opened at GBX 1,489 ($19.45) on Tuesday. The company has a current ratio of 5.58, a quick ratio of 4.79 and a debt-to-equity ratio of 18.58. The business’s 50 day simple moving average is GBX 1,432.96 and its 200-day simple moving average is GBX 1,437.99. The stock has a market capitalization of £3.38 billion and a price-to-earnings ratio of -1,654.44. Abcam has a twelve month low of GBX 1,142 ($14.92) and a twelve month high of GBX 1,740 ($22.73).

About Abcam

Abcam plc, a life sciences company, researches, develops, and distributes biological reagents and tools for research, drug discovery, and diagnostics in the United States, China, Japan, Europe, the Middle East, Africa, and rest of Asia Pacific. The company offers various research products, including primary and secondary antibodies; ELISA and matched antibody pairs; cell and tissue imaging tools; cellular and biochemical assays; proteins and peptides; proteomics tools; agonists, antagonists, activators, and inhibitors; lysates; and multiplex assays.

Featured Story: What are Bollinger Bands?

Analyst Recommendations for Abcam (LON:ABC)

Receive News & Ratings for Abcam Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abcam and related companies with's FREE daily email newsletter.